Synopsis A recent clinical study demonstrates that the combination of gemcitabine and capecitabine is the treatment of choice in the adjuvant setting after resection for pancreatic ductal adenocarcinoma. This week's ' MED FACT ' discusses a clinical trial from The Lancet , “C omparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial ”. March 2017.
Authors : Neoptolemos JP; Palmer DH; Ghaneh P; Psarelli EE; Valle JW; Halloran CM; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S. Key Takeaways Adjuvant gemcitabine plus capecitabine is an effective approach for pancreatic ductal adenocarcinoma. Objective Study Type Participants To evaluate the efficacy and safety of gemcitabine and capecitabine compared with gemcitabine monotherapy for resected pancreatic…
